164 related articles for article (PubMed ID: 36470426)
1. Mapping the KRAS proteoform landscape in colorectal cancer identifies truncated KRAS4B that decreases MAPK signaling.
Adams LM; DeHart CJ; Drown BS; Anderson LC; Bocik W; Boja ES; Hiltke TM; Hendrickson CL; Rodriguez H; Caldwell M; Vafabakhsh R; Kelleher NL
J Biol Chem; 2023 Jan; 299(1):102768. PubMed ID: 36470426
[TBL] [Abstract][Full Text] [Related]
2. Precise characterization of KRAS4b proteoforms in human colorectal cells and tumors reveals mutation/modification cross-talk.
Ntai I; Fornelli L; DeHart CJ; Hutton JE; Doubleday PF; LeDuc RD; van Nispen AJ; Fellers RT; Whiteley G; Boja ES; Rodriguez H; Kelleher NL
Proc Natl Acad Sci U S A; 2018 Apr; 115(16):4140-4145. PubMed ID: 29610327
[TBL] [Abstract][Full Text] [Related]
3. Precise Characterization of KRAS4B Proteoforms by Combining Immunoprecipitation with Top-Down Mass Spectrometry.
Adams LM; DeHart CJ; Kelleher NL
Methods Mol Biol; 2021; 2262():47-64. PubMed ID: 33977470
[TBL] [Abstract][Full Text] [Related]
4. KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform.
Salmón M; Paniagua G; Lechuga CG; Fernández-García F; Zarzuela E; Álvarez-Díaz R; Musteanu M; Guerra C; Caleiras E; Muñoz J; Ortega S; Drosten M; Barbacid M
Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301865
[TBL] [Abstract][Full Text] [Related]
5. Differential functions of the KRAS splice variants.
Kochen Rossi J; Nuevo-Tapioles C; Philips MR
Biochem Soc Trans; 2023 Jun; 51(3):1191-1199. PubMed ID: 37222266
[TBL] [Abstract][Full Text] [Related]
6. FLAG-KRAS4B as a Model System for KRAS4B Proteoform and PTM Evaluation by Mass Spectrometry.
D'Ippolito RA; Scheidemantle GM; Smith BP; Powell K; Eury S; Neish A; Mehalko J; Beaumont L; Fer N; Wall V; Burgan W; Maciag AE; Esposito D; DeHart CJ
Methods Mol Biol; 2024; 2797():299-322. PubMed ID: 38570469
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of KRAS4a and KRAS4b splice variants reveals distinctive structural and functional properties.
Whitley MJ; Tran TH; Rigby M; Yi M; Dharmaiah S; Waybright TJ; Ramakrishnan N; Perkins S; Taylor T; Messing S; Esposito D; Nissley DV; McCormick F; Stephen AG; Turbyville T; Cornilescu G; Simanshu DK
Sci Adv; 2024 Feb; 10(7):eadj4137. PubMed ID: 38354232
[No Abstract] [Full Text] [Related]
9. Ras protein abundance correlates with Ras isoform mutation patterns in cancer.
Hood FE; Sahraoui YM; Jenkins RE; Prior IA
Oncogene; 2023 Apr; 42(15):1224-1232. PubMed ID: 36864243
[TBL] [Abstract][Full Text] [Related]
10. KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab.
Chiari R; Palladino S; Emili R; De Lisa M; Sarti D; Catalano V; Magnani M; Graziano F; Ruzzo A
Sci Rep; 2023 Nov; 13(1):21036. PubMed ID: 38030703
[TBL] [Abstract][Full Text] [Related]
11. The small organic molecule C19 binds and strengthens the KRAS4b-PDEδ complex and inhibits growth of colorectal cancer cells in vitro and in vivo.
Cruz-Nova P; Schnoor M; Correa-Basurto J; Bello M; Briseño-Diaz P; Rojo-Domínguez A; Ortiz-Mendoza CM; Guerrero-Aguirre J; García-Vázquez FJ; Hernández-Rivas R; Thompson-Bonilla MDR; Vargas M
BMC Cancer; 2018 Nov; 18(1):1056. PubMed ID: 30382908
[TBL] [Abstract][Full Text] [Related]
12. The Human Proteoform Atlas: a FAIR community resource for experimentally derived proteoforms.
Hollas MAR; Robey MT; Fellers RT; LeDuc RD; Thomas PM; Kelleher NL
Nucleic Acids Res; 2022 Jan; 50(D1):D526-D533. PubMed ID: 34986596
[TBL] [Abstract][Full Text] [Related]
13. Is Nanoclustering essential for all oncogenic KRas pathways? Can it explain why wild-type KRas can inhibit its oncogenic variant?
Nussinov R; Tsai CJ; Jang H
Semin Cancer Biol; 2019 Feb; 54():114-120. PubMed ID: 29307569
[TBL] [Abstract][Full Text] [Related]
14. Structural basis of recognition of farnesylated and methylated KRAS4b by PDEδ.
Dharmaiah S; Bindu L; Tran TH; Gillette WK; Frank PH; Ghirlando R; Nissley DV; Esposito D; McCormick F; Stephen AG; Simanshu DK
Proc Natl Acad Sci U S A; 2016 Nov; 113(44):E6766-E6775. PubMed ID: 27791178
[TBL] [Abstract][Full Text] [Related]
15. The role of KRAS splice variants in cancer biology.
Nuevo-Tapioles C; Philips MR
Front Cell Dev Biol; 2022; 10():1033348. PubMed ID: 36393833
[TBL] [Abstract][Full Text] [Related]
16. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
17. The G protein-coupled receptor GPR31 promotes membrane association of KRAS.
Fehrenbacher N; Tojal da Silva I; Ramirez C; Zhou Y; Cho KJ; Kuchay S; Shi J; Thomas S; Pagano M; Hancock JF; Bar-Sagi D; Philips MR
J Cell Biol; 2017 Aug; 216(8):2329-2338. PubMed ID: 28619714
[TBL] [Abstract][Full Text] [Related]
18. Targeting KRAS4A splicing through the RBM39/DCAF15 pathway inhibits cancer stem cells.
Chen WC; To MD; Westcott PMK; Delrosario R; Kim IJ; Philips M; Tran Q; Bollam SR; Goodarzi H; Bayani N; Mirzoeva O; Balmain A
Nat Commun; 2021 Jul; 12(1):4288. PubMed ID: 34257283
[TBL] [Abstract][Full Text] [Related]
19. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
[TBL] [Abstract][Full Text] [Related]
20. Origin and Evolution of RAS Membrane Targeting.
García-España A; Philips MR
Oncogene; 2023 May; 42(21):1741-1750. PubMed ID: 37031342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
